The new hardware expands Garvan's current system so that it can better support large-scale whole-genome and single-cell sequencing initiatives.
It will be possible to upload genomic data to Australia's My Health Record system, which has raised privacy issues, the Sydney Morning Herald reports.
The Garvan team has shown that whole-genome sequencing can diagnose more cases than targeted panels and is now demonstrating its cost-effectiveness.
With the new five-year funding, patients across Australia with rare or less common cancers will be able to access the program through a network of eight cancer centers.
Clearbridge will refer its patients to Genome.One's GoExplore test for disease risk assessment and drug response prediction.
Australia's Garvan Institute is teaming up with startup E-Nome to explore how secure storage of personal genomic records could support medical research.
The Garvan Institute's Genome.One plans to expand to a network of general practitioners, the Australian Financial Review reports.
The two firms are offering a combined genetic disease risk and pharmacogenomic analysis that covers 49 conditions and about 220 medications.
A new Australian service offers whole-genome sequencing and a health assessment, the Sydney Morning Herald reports.
An Australian team has sequenced and mapped the genome of a prostate cancer tumor, as the Australian Financial Review reports.
Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.
Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.
Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.
In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.